Stroke in Patients Undergoing Dialysis

United States Renal Data System: USRDS 1999 Annual Data Report, Bethesda, MD, The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1999.

Lindner A. , Charra B. , Sherrard D.J. , Scribner B.H. . Accelerated atherosclerosis in prolonged hemodialysis. N Engl J Med 1974; 290: 697–701.

Lundin A.P. , Friedman E.A. . Vascular consequences of maintenance hemodialysis-An unproven case. Nephron 1978; 21: 177–80.

Burke I.F. , Francos C.J.C. , Moore L.L. , Cho S.Y. , Lasker N. . Accelerated atherosclerosis in chronic hemodialysis patients: Another look. Nephron 1978; 21: 181–5.

Iseki K. , Kinjo K. , Kimura Y. , Osawa A. , Fukiyama K. . Evidence of high risk of cerebral hemorrhage in chronic dialysis patients. Kidney Int 1993; 44: 1086–90.

Weber D.L. , Reagan T. , Leeds M. . Intracerebral hemorrhage during hemodialysis. NY State Med 1972; 72: 1853–4.

Onoyama K. , Kumagal H. , Miishima T. . Incidence of strokes and its prognosis in patients on maintenance hemodialysis. Jpn Heart J 1986; 27: 685–91.

Chachati A. , Dechenne C. , Godon J.P. . Increased incidence of cerebral hemorrhage mortality in patients with analgesic nephropathy on hemodialysis. Nephron 1987; 45: 167–8.

Siddiqui J.Y. , Fitz A.E. , Lawton R.L. , Kirkendall W.M. . Causes of death in patients receiving long-term hemodialysis. JAMA 1970; 212: 1350.

Robins M. , Baum H.M. . The national survey of stroke incidence. Stroke 1981; 12(Suppl 1): S45–57.

Tanaka H. , Ueda Y. , Hayashi M. . Risk factors for cerebral hemorrhage and cerebral infarction in a Japanese rural community. Stroke 1982; 13: 62–73.

Mattana J. , Effiong C. , Gooneratne P. , Singhal P.C. . Outcome of stroke in patients undergoing hemodialysis. Arch Intern Med 1998; 158: 537–41.

Iseki K. , Fukiyama K. . Predictors of stroke in patients receiving chronic hemodialysis. Kidney Int 1996; 50: 1672–5.

World Health Organization. International Classification of Diseases, Ninth Revision (1CD-9). Geneva, Switzerland: World Health Organization, 1977.

Palfrey P.S. , Foley R.N. , Harnett J.D. , Kent G.M. , Murray D. , Barre P.E. . Outcome and risk factors of ischemic heart disease in chronic uremic. Kidney Int 1996; 49: 1428–34.

HCFA-1995. 1995 Annual Report. ESRD core indicators project. Opportunities to improve care for adult in-center hemodialysis patients. Baltimore, MD, Health Care Financing Administration, DHHS, January 1996.

Rocco M.V. , Flanigan M.J. , Beaver S. . Report from the 1995 Core Indicators for Peritoneal Dialysis Study Group. Am J Kidney Dis 1997; 30: 165–73.

Rahman M. , Dixit A. , Donley V. . Factors associated with inadequate blood pressure control in hypertensive hemodialysis patients. Am J Kidney Dis 1999; 33: 498–506.

Zucchelli P. , Santoro A. , Zuccala Z. . Genesis and control of hypertension in hemodialysis patients. Semin Nephrol 1988; 8: 163.

Salem M.M. . Hypertension in the hemodialysis population: A survey of 649 patients. Am J Kidney Dis 1995; 26: 461.

Mailloux L.U. , Haley W.E. . Hypertension in the ESRD patient: Pathophysiology, therapy, outcomes, and future direction. Am J Kidney Dis 1998; 32: 705–19.

Converse R.L. , Jacobsen T.N. , Toro R.D. . Survival as an index of adequacy of dialysis. Kidney Int 1992; 41: 1286.

Raine A.E. , Roger S.D. . Effect of erythopoietin on blood pressure. Am J Kidney Dis 1991; 18(Suppl 1): S76–83.

Shichiri M. , Hirata Y. , Ando K. . Plasma endothelin levels in hypertension and chronic renal failure. Hypertension 1990; 15: 493–6.

Koyama H. , Tabata T. , Nishizawa Y. . Plasma endothelin levels in patients with uremia. Lancet 1989; 1: 991.

Suzuki N. , Matsumoto H. , Miyauchi T. . Endothelin-3 concentrations in human plasma: The increased concentrations in patients undergoing hemodialysis. Biochem Biophys Res Commun 1990; 169: 809–15.

Vailante P. , Leone A. , Calver A. . Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572–5.

Appel G. . Lipid abnormalities in renal disease. Kidney Int 1991; 39: 169–83.

Castelli W.P. . Epidemiology of triglycerides: A view from Framingham. Am J Cardiol 1992; 70: 3H–9H.

King W.M. , Greene E.L. , Raij L. . Cardiovascular risk factors in chronic renal failure and hemodialysis population. Am J Kidney Dis 1992; 19: 505–13.

Cheung A.K. , Wu L.L. , Kablitz C. , Leypoldt J.K. . Atherogenic lipids and lipoproteins in hemodialysis patients. Am J Kidney Dis 1993; 22: 271–6.

Steinber D. , Parthasarathy S. , Care T.E. , Khoo J.C. , Witztum J.L. . Beyond cholesterol: Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915–24.

Kronenberg F. , Kathrein H. , Konig P. . Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. Arterioscl and Thromb 1994; 14: 1405–11.

Parra H.I. , Mezdour H. , Caehera C. , Dracon M. , Taequet A. , Fmchart J.C. . Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis. Clin Chem 1987; 33: 721.

Cressman M.D. , Heyka R.J. , Paganini E.P. , O'Neil J. , Skibinski C.I. , Hoff H.F. . Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992; 86: 475–82.

Clarke R. , Daly L. , Robinson K. . Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149–55.

Lupattelli G. , Rufini S. , Locati E.H. . Hyperhomocysteinemia is associated with carotid atherosclerosis. Angiology 1999; 50(10): 823–30.

Bostom A.G. , Rosenberg I.H. , Silbershatz H. . Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: The Framingham Study. Ann Int Med 1999; 131(5): 352–55.

Chauveau P. , Chadefaux B. , Coude M. . Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 1993; 43(suppl. 41): S72–7.

Bachmann J. , Tepel M. , Raidt H. . Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. JASN 1995; 6: 121–5.

Pascarlo L. , Bianco F. , Giorgini A. . Echo color doppler imaging of carotid vessels in hemodialysis patients. Evidence of high levels of atherosclerotic lesions. Am J Kidney Dis 1996; 28: 713–720.

Rossi A. , Bonfante L. , Giacomini A. . Carotid artery lesions in patients with nondiabetic chronic renal failure. Am J Kidney Dis 1996; 27: 58–66.

Jubiliber S.J. . Hemostatic abnormalities in renal disease. Am Kidney Dis 1985; 5: 219–25.

Wihelmsen L. , Svardsudd K. , Korsan-Bengtsen K. , Larsson B. , Welin L. , Tibblin G. . Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501–5.

Friedman P J. . Serum creatinine: an independent predictor of survival after stroke. J Int Med Res 1991; 229: 175–9.

Bloembergen W.E. , Port F.K. , Manger E.A. , Wolfe R.A. . A comparison of cause of death between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol 1995; 6: 184–91.

Maiorca R. , Vonesh E. , Cancarini G.C. . A six-year comparison of patient and technique survivals in CAPD and HD. Kidney Int 1988; 34: 518–24.

Maiorca R. , Vonesh E.F. , Cavalli P. . A multicenter, selection-adjusted comparison of patient and technique survivals on CAPD and hemodialysis. Perit Dial Int 1991; 11: 118–27.

Mattana J. , Effiong C. , Gooneratne R. , Singhal P.C. . Risk of fatal cerebrovascular accident in patients on peritoneal dialysis versus hemodialysis. J Am Soc Nephrol 1997; 8: 1342–7.

Hankey G.J. , Warlow C.P. . Treatment and secondary prevention of stroke: evidence, cost, and effects on individuals and populations. Lancet 1999; 354: 1457–63.

PROGRESS Management Committee. Blood pressure lowering for the secondary prevention of stroke: rationale and design for PROGRESS (Perindopril Protection Against Recurrent Stroke Study). J Hypertens 1996; 14(Suppl 2): S41–6.

The INDIANA (Individual Data Analysis of Antihypertensive intervention Trials) Project Collaborators. Effect of antihypertensive treatment in patients having already suffered from stroke: gathering the evidence. Stroke 1997; 28: 2557–62.

Rodgers A. , Neal B. , MaeMahon S. . The effects of blood pressure lowering in cerebrovascular disease. Neurol Rev Int 1997; 2: 12–5.

Charra B. , Calemard E. , Ruffet M. . Plasma endothelin levels in hypertension and chronic renal failure. Hypertension 1990; 15: 493.

Flanigan M J. , Khairullah Q.T. , Lim V.S. . Dialysate sodium delivery can alter chronic blood pressure measurement. Am J Kidney Dis 1997; 29: 383–91.

Zazgornik J. , Biesenbach G. , Forstenlehner M. , Stummvoll K. . Profile of antihypertensive drugs in hypertensive patients on renal replacement therapy (RRT). Clin Nephrol 1997; 48: 337–40.

London G.M. , Marchais S J. , Guerin A.P. . Salt and water retention and calcium blockade in uremia. Circulation 1990; 82: 105–13.

Jamrozik K. , Broadhurst R.J. , Anderson C.S. , Stewart-Wynne E.G. . The role of lifestyle factors in the etiology of stroke: a population based case-control study in Perth, Western Australia. Stroke 1994; 25: 51–9.

Hahkey G.J. . Smoking and risk of stroke. J Cardiovasc Risk 5: 1999; 207–11.

Furie K.L. , Wilterdink J.L. , Kistler J.P. . Risk factor management and medical therapy of carotid artery stenosis. UpTo Date: 1999; 7.

Bucher H.C. , Griffith L.E. , Guyatt G.H. . Effect of HMG CoA reductase inhibitors on stroke: a meta-analysis of randomized, controlled trials. Am Intern Med 1998; 128: 89–95.

The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. 1998; 339: 1349–57.

Plehn I.F. , Davis B.R. , Sacks F.M. . Reduction of stroke incidence after myocardial infarction with pravastatin. The Cholesterol and Recurrent Events (CARE) Study. Circulation 1999; 99: 216–23.

Algra A. , Van Gijn J. . Aspirin at any dose above 30 mg offers only modest protection after cerebral ischemia. J Neurol meurosurg Psychiatry 1996; 60: 197–9.

Hankey G.J. . One year after CAPRIE, IST and ESPS 2: any changes in concepts? Cerebrovasc Dis 8 (suppl 5): s1–7, 1998.

Gent M. , Easton I.D. , Hachinski V. . The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; I: 1215.

Hass W.K. , Easton J.D. , Adams H.P. . A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: 501–7.

Hankey G.J. , Warlow C.P. . Transient ischaemic attacks of the brain and eye. London: W.B. Saunders, 1994.

Koudstaal P. . Secondary prevention following stroke or TIA in patients with nonrheumatic atria/fibrillation: anticoagulant therapy versus control (Cochrane review). In: The Cochrane Library, Oxford: Update Software, 1999.

Hankey G.J. , Slattery J.M. , Warlow C.P. . The prognosis of hospital-referred transient ischemic attacks. J Neurol Neurosurg Psychiatry 1991; 54: 793–802.

European Carotid Surgery Trialists’ Collaborative Group. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998; 351: 1379–87.